Baseline creatinine predicts acute kidney injury during intensive therapy in transplant-eligible patients with acute myeloid leukaemia

Br J Haematol. 2022 Feb;196(3):781-784. doi: 10.1111/bjh.17854. Epub 2021 Oct 5.

Authors

Stefan Krieg¹, Harald Seeger², Patrick Hofmann³, Carmen Del Prete¹, Markus G Manz¹, Antonia M Müller¹, Alexandre P A Theocharides¹

Affiliations

¹ Department of Medical Oncology and Haematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
² Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
³ Institute of Physiology, University of Zurich, Zurich, Switzerland.

PMID: 34611894
DOI: 10.1111/bjh.17854

No abstract available

Keywords: acute myeloid leukaemia; chemotherapy; clinical haematology; leukaemia therapy; transplantation.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Acute Kidney Injury / diagnosis*
Acute Kidney Injury / etiology*
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers
Creatinine / blood*
Female
Glomerular Filtration Rate
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute / complications*
Leukemia, Myeloid, Acute / drug therapy
Male
Middle Aged
Preoperative Care* / adverse effects
Preoperative Care* / methods
Prognosis
Retrospective Studies
Young Adult

Substances

Biomarkers
Creatinine